InBrain Pharma, a Lille biotechnology start-up developing therapeutic solutions against brain diseases, receives authorization from the French National Agency for Drug Safety (ANSM) to treat with the DIVE technology (Dopamine IntracerebroVentriculairE) their first patients with Parkinson's disease (phase I / IIb study).
Parkinson's disease is characterized by a deficit of cerebral dopamine. The concept developed by InBrain Pharma is to administer the missing dopamine in a controlled and localized manner, adapting it to the physiological needs of the brain, just like administering insulin to treat diabetes. This therapeutic innovation could improve the quality of life of patients suffering from Parkinson's disease at a stage where oral dopaminergic treatments are not satisfactory enough.
The success of this project is the result of more than ten years of academic and industrial research conducted by the team of Pr. David Devos (Pharmacology, CHU-Lille, Univ. Lille Neuroscience & Cognition, Inserm, UMR-S1172), Pr. Caroline Moreau (Parkinson's disease expert center) and the team of Pr. Pascal Odou (Research Group on Injectable Forms and Associated Technologies). Since its creation in July 2018, the team of InBrain Pharma has been mobilized to start this therapeutic trial in the best conditions.
Thanks to the excellence and the social utility of its research, InBrain Pharma has benefited from the support of the whole ecosystem of Hauts de France: the University of Lille, the University Hospital of Lille (including the Department of Medical Pharmacology and Pharmacy Centrale), the Lille University Foundation, SATT Nord, the Hauts de France region, Nord France Amorçage, FINOVAM and Eurasanté.
This DIVE-1 study will begin on the first 20 patients in the coming weeks in close collaboration with the Lille University Hospital (expert center for Parkinson's disease, Medical Pharmacology, Institute of Pharmacy, Department of Research and Innovation, Center for Clinical Investigation).
Following this first project, InBrain Pharma will develop other innovative strategies to fight brain diseases and improve the lives of patients.